Medicare AdvantageCoverageMedium impact
MA08.016h, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Pulmonology, Cardiology, Internal Medicine·Pharmacy
Effective date
Jun 10, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of the Medicare Advantage policy MA08.016h governing the treatment of pulmonary artery hypertension (PAH) using intravenous, subcutaneous, and inhaled medications. The policy took effect on 06/10/2026 and was reissued on the same date. Without access to the full policy text, the specific changes from previous versions cannot be determined; however, the billing team must review this reissued policy to identify any updates to coverage criteria, prior authorization requirements, or billing guidance for PAH pharmacologic agents.
Action Required
By 06/10/2026: Billing and clinical teams must obtain and review the complete policy text from the provided URL. Identify specific medications, HCPCS codes (likely J-codes for intravenous and subcutaneous agents, and inhaled agents), and any changes to prior authorization requirements or coverage limitations. Update billing system rules, encounter templates, and prior authorization workflows as needed to reflect new or modified requirements. Communicate changes to providers and clinical staff. Verify that all PAH medication claims submitted after 06/10/2026 comply with the reissued policy terms. Claims submitted without compliance may be denied.